Abstract:Major depressive disorder is one of the primary causes of disability and disease worldwide. The therapy of depression is prevalently based on monoamine reuptake blockers; consequently, investigations aimed to clarify the aetiology of depression have mostly looked at brain areas innervated by monamines and brain circuitry involved in inputs and outputs of these areas. The recent approval of esketamine as a rapid-acting antidepressant drug in treatment-resistant depression, has definitively projected glutamatergic transmission as a key constituent in the use of new drugs in antidepressant therapy. In this review we have examined the role of several brain areas: namely, the hippocampus, the medial Prefrontal Cortex (mPFC), the nucleus accumbens (NAc), the Lateral Habenula (LHb), the amygdala and the Bed Nucleus of Stria Terminalis (BNST). The reason for undertaking an in-depth review is due to their significant role in animal models of depression, which highlight their inter-connections as well as their inputs and outputs. In particular, we examined the modification of the expression and release of the brain derived neurotrophic factor (BDNF) and associated changes in dendritic density induced by chronic stress in the above areas of animal models of depression (AnMD). We also examined the effectiveness of ketamine and standard antidepressants in reversing these alterations, with the aim of identifying a brain circuit where pathological alteration might trigger the appearance of depression symptoms. Based on the role that these brain areas play in the generation of the symptoms of depression, we assumed that the mPFC, the NAc/Ventral Tegmental Area (VTA) and the hippocampus form a primary circuit of depression, where regular performance can endure resilience to stress. We have also examined how this circuit is affected by environmental challenges and how the activation of one or more areas, including amygdala, LHb or BNST can produce local detrimental effects that spread over specific circuits and generate depression symptoms. Furthermore, we also examined how, through their outputs, these three areas can negatively influence the NAc/VTA-PFC circuit directly or through the BNST, to generate anhedonia, one of the most devastating symptoms of depression.

Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression

Neuroplasticity and depression: Rewiring the brain's networks through pharmacological therapy (Review)

5-HT2A mediated plasticity as a target in major depression: a narrative review connecting the dots from neurobiology to cognition and psychology

Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications

The neurobiology of depression—revisiting the serotonin hypothesis. II. Genetic, epigenetic and clinical studies

Neuroplasticity: Pathophysiology and Role in Major Depressive Disorder

From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder

Changes in Hippocampal Plasticity in Depression and Therapeutic Approaches Influencing These Changes

Serotonin is a common thread linking different classes of antidepressants

The involvement of serotonin in major depression: nescience in disguise?

Depressive disorder and antidepressants from an epigenetic point of view

Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model

Synapse Regression in Depression: The Role of 5-HT Receptors in Modulating NMDA Receptor Function and Synaptic Plasticity

Serotonergic gene expression and depression: implications for developing novel antidepressants

Structural neural plasticity evoked by rapid-acting antidepressant interventions

Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections

New perspective on sustained antidepressant effect: focus on neurexins regulating synaptic plasticity

Synaptic plasticity in depression: molecular, cellular and functional correlates

BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression